*Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC;

†McAllister Heart Institute, University of North Carolina School of Medicine, Chapel Hill, NC;

‡Department of Physiology, East Carolina University Brody School of Medicine, Greenville, NC;

§East Carolina University Diabetes and Obesity Institute, Greenville, NC; and

¶Department of Medicine, Division of Cardiology, University of North Carolina School of Medicine, Chapel Hill, NC.

Correspondence: Brian C. Jensen, MD, UNC Division of Cardiology, 160 Dental Circle, CB 7075 Chapel Hill, NC 27599-7075 (e-mail: [email protected]).

1. P. B. Sandroni: NIH (Predoctoral Training Program in Integrative Vascular Biology 5T32HL069768 to UNC) and NIH (Predoctoral Training Program in Translational Medicine T32GM122741 to UNC). 2. B. C. Jensen: NIH (R01HL140067) and Hugh A. McAllister Research Foundation

The University of North Carolina owns a patent with BCJ as an inventor for the use of alpha-1-adrenergic receptor agonists for the treatment of heart failure.

The authors report no conflicts of interest.